Multiple competitors have now confirmed the launch of Canadian biosimilar versions of the world’s biggest-selling drug, Humira.
Four further Canadian competitors on Humira (adalimumab) have confirmed launch alongside Sandoz, opening the market up to immediate multi-source competition from five biosimilars to the world’s biggest-selling medicine.
Viatris has announced the launch of its Hulio version – licensed from Fujifilm Kyowa Kirin Biologics – while Merck Canada has confirmed the introduction of Samsung Bioepis’ Hadlima biosimilar
Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”
Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.
Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.
